Lilly Buys Psychedelic Drugmaker AtaiBeckley for $3.8 Billion

Summary

Eli Lilly agreed to buy psychedelic drugmaker AtaiBeckley for up to $3.8 billion, highlighting rising large-pharma interest in psychedelic medicine. AtaiBeckley's lead compound BPL-003 is a DMT-derived intranasal spray for treatment-resistant depression. Reporter Madison Muller explains that J&J's already-approved Spravato has built the clinical infrastructure for such therapies and became a blockbuster, while FDA and political support are improving acceptance of the space.

• Eli Lilly acquires AtaiBeckley for up to $3.8B, entering the psychedelic drug development space.
• AtaiBeckley's lead drug BPL-003 is a DMT-related intranasal spray for treatment-resistant depression.
• J&J's Spravato (esketamine) paved the way: approved 5+ years ago, now a blockbuster with established clinic infrastructure.
• Clinics now comfortable with monitored administration required for these intranasal therapies.
• FDA is more accepting of psychedelic-like medications than in the past.
• Trump administration taking steps to loosen restrictions on psychedelic drug research.
• Multiple companies nearing late-stage testing and potential FDA approval in the psychedelic space.